Stocktoria
Aprea Therapeutics, Inc. APRE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-10-03
Aprea Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | — | — | — | — | $23.9M |
| Operating income | -$13.2M | -$14.3M | -$15.5M | -$113.4M | -$37.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$12.6M | -$13.0M | -$14.3M | -$112.7M | -$37.1M |
| EPS (diluted) | $-1.93 | $-2.35 | $-3.95 | $-67.99 | $-34.88 |
| Operating cash flow | -$12.9M | -$13.6M | -$12.2M | -$25.0M | -$37.7M |
| Free cash flow | — | -$13.6M | -$12.3M | — | — |
| Cash & equivalents | $14.6M | $22.8M | $21.6M | $28.8M | $53.1M |
| Total assets | $15.9M | $24.0M | $22.7M | $30.2M | $56.8M |
| Total liabilities | — | — | — | $3.2M | $7.3M |
| Shareholders' equity | $12.4M | $19.3M | $17.0M | $25.6M | $49.5M |
Source: SEC EDGAR filings · CIK 0001781983 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.